Crescent Grove Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $323K | Buy |
5,330
+500
| +10% | +$29.1K | 0.03% | 229 |
|
|
2025
Q4 | $261K | Buy |
+4,830
| New | +$232K | 0.02% | 253 |
|
|
2025
Q3 | – | Sell |
-4,430
| Closed | -$205K | – | 294 |
|
|
2025
Q2 | $205K | Hold |
4,430
| – | – | 0.02% | 273 |
|
|
2025
Q1 | $270K | Buy |
4,430
+81
| +2% | +$4.72K | 0.03% | 222 |
|
|
2024
Q4 | $246K | Buy |
4,349
+459
| +12% | +$25.6K | 0.02% | 248 |
|
|
2024
Q3 | $201K | Sell |
3,890
-1,200
| -24% | -$56.3K | 0.02% | 268 |
|
|
2024
Q2 | $211K | Sell |
5,090
-5,785
| -53% | -$259K | 0.02% | 262 |
|
|
2024
Q1 | $590K | Sell |
10,875
-950
| -8% | -$48.4K | 0.06% | 162 |
|
|
2023
Q4 | $607K | Buy |
11,825
+1,095
| +10% | +$57.5K | 0.07% | 153 |
|
|
2023
Q3 | $623K | Sell |
10,730
-5,893
| -35% | -$361K | 0.08% | 145 |
|
|
2023
Q2 | $1.06M | Buy |
16,623
+2,464
| +17% | +$165K | 0.11% | 108 |
|
|
2023
Q1 | $981K | Sell |
14,159
-1,604
| -10% | -$113K | 0.11% | 107 |
|
|
2022
Q4 | $1.13M | Buy |
15,763
+1,483
| +10% | +$112K | 0.12% | 107 |
|
|
2022
Q3 | $1.01M | Buy |
14,280
+3,735
| +35% | +$271K | 0.12% | 96 |
|
|
2022
Q2 | $818K | Sell |
10,545
-6,200
| -37% | -$472K | 0.09% | 120 |
|
|
2022
Q1 | $1.23M | Buy |
16,745
+1,555
| +10% | +$104K | 0.12% | 94 |
|
|
2021
Q4 | $947K | Buy |
15,190
+5,645
| +59% | +$331K | 0.09% | 121 |
|
|
2021
Q3 | $569K | Sell |
9,545
-3,600
| -27% | -$237K | 0.06% | 141 |
|
|
2021
Q2 | $878K | Sell |
13,145
-800
| -6% | -$52.2K | 0.09% | 114 |
|
|
2021
Q1 | $887K | Sell |
13,945
-200
| -1% | -$12.4K | 0.1% | 101 |
|
|
2020
Q4 | $884K | Buy |
14,145
+45
| +0.3% | +$2.77K | 0.12% | 78 |
|
|
2020
Q3 | $850K | Buy |
14,100
+90
| +0.6% | +$5.42K | 0.17% | 74 |
|
|
2020
Q2 | $824K | Buy |
14,010
+310
| +2% | +$18.5K | 0.17% | 68 |
|
|
2020
Q1 | $764K | Hold |
13,700
| – | – | 0.17% | 59 |
|
|
2019
Q4 | $879K | Buy |
13,700
+200
| +1% | +$11.5K | 0.15% | 74 |
|
|
2019
Q3 | $685K | Hold |
13,500
| – | – | 0.13% | 72 |
|
|
2019
Q2 | $612K | Sell |
13,500
-3,181
| -19% | -$148K | 0.12% | 80 |
|
|
2019
Q1 | $796K | Buy |
16,681
+24
| +0.1% | +$1.2K | 0.16% | 67 |
|
|
2018
Q4 | $866K | Buy |
16,657
+1,000
| +6% | +$53.7K | 0.18% | 68 |
|
|
2018
Q3 | $972K | Hold |
15,657
| – | – | 0.21% | 57 |
|
|
2018
Q2 | $866K | Buy |
15,657
+1,000
| +7% | +$54K | 0.21% | 60 |
|
|
2018
Q1 | $927K | Hold |
14,657
| – | – | 0.23% | 57 |
|
|
2017
Q4 | $898K | Sell |
14,657
-300
| -2% | -$18.8K | 0.23% | 56 |
|
|
2017
Q3 | $953K | Hold |
14,957
| – | – | 0.24% | 55 |
|
|
2017
Q2 | $833K | Buy |
+14,957
| New | +$814K | 0.24% | 56 |
|
Other funds holding BMY
VCM
VPM
Crescent Grove Advisors's BMY Position: Q1 2026 in Review
Crescent Grove Advisors increased its Bristol-Myers Squibb (BMY) stake by 10% in Q1 2026, buying an estimated $29.1K and bringing the position to 5,330 shares worth $323K. The position accounts for 0.03% of the portfolio, ranked #229.
Crescent Grove Advisors first reported a position in BMY in Q2 2017 and has held it in 35 quarters since. The position peaked at $1.23M in Q1 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Crescent Grove Advisors held 5,330 shares of Bristol-Myers Squibb worth $323K as of Q1 2026.
- Crescent Grove Advisors bought 500 Bristol-Myers Squibb shares in Q1 2026, an estimated $29.1K.
- Bristol-Myers Squibb made up 0.03% of Crescent Grove Advisors's portfolio in Q1 2026, its #229 holding.
- Crescent Grove Advisors first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 35 quarters since.
- Crescent Grove Advisors's Bristol-Myers Squibb position peaked at $1.23M in Q1 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.